<JPM Research> Favors CHINA LIFE and PING AN for Better Growth Potential Compared to Regional Competitors
Record Sales in Hong Kong's Life Insurance: Hong Kong's life insurance industry achieved a record high in new life sales volume for 3Q25, with first-year premium (FYP) reaching HKD91 billion, a 69% year-on-year increase, according to JPMorgan.
Concerns Over Product Mix and Growth Management: Despite the record sales, the overall product mix and business development are considered less healthy, with JPMorgan emphasizing the importance of managing growth momentum in 2026 amid tightening regulations.
Impact of Regulatory Changes on Sales Commissions: The Hong Kong Insurance Authority plans to reduce upfront sales commissions starting January 2026, leading to a significant increase in broker channel contributions, which accounted for 35% of new premium sales in 3Q25, up 8 percentage points year-on-year.
Investment Preferences for 2026: JPMorgan favors CHINA LIFE and PING AN for 2026, citing their superior business growth prospects compared to other regional peers.
Trade with 70% Backtested Accuracy
Analyst Views on 02318
About the author
Citi's Ratings and Target Prices for Chinese Insurers (Table)
Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.
Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".
Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.
Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.
Citi Reports: Upcoming Results Season for Chinese Insurers; China Life Anticipated to Top NBV Growth
Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.
Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.
Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.
Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.
Citi Places CPIC on 90-Day Negative Watch, Anticipates FY25 Performance to Fall Behind Competitors
Citi's Negative Catalyst Watch on CPIC: Citi has initiated a 90-day negative catalyst watch on CPIC (02601.HK), predicting that its FY25 results will underperform compared to peers, with a projected 28% growth in new life insurance business.
Comparative Performance Expectations: The anticipated combined operating ratio for CPIC in FY25 is 98.0%, which is less favorable than major competitors like PICC GROUP and PING AN, whose ratios are forecasted at 97.3% and 97.1%, respectively.
Earnings Growth Projections: CPIC's projected 16% year-over-year earnings increase for FY25 is significantly lower than the expected growth rates of its competitors, such as CHINA TAIPING at 220% and CHINA LIFE at 47%.
Citi's Rating and Target Price: Despite the negative outlook, Citi has rated CPIC as a Buy and set a target price of HKD 44.9.
<Midday Update> HSI Ends Midday at 26,705, Gaining 138 Points; HSTI Reaches 5,367, Up 7 Points; ZIJIN MINING Surges Over 4%; HK & CHINA GAS, CK ASSET, WH GROUP, TIANGONG INT'L, and CONCH VENTURE Achieve New Record Highs
Market Performance: The Hang Seng Index (HSI) rose by 138 points (0.5%) to 26,705, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw slight gains.
Active Heavyweights: Notable movements included HKEX (+0.9%), PING AN (+0.4%), and TENCENT (+0.2%), while XIAOMI, BABA, and MEITUAN experienced minor declines.
Significant Movers: ZIJIN MINING surged by 4.7%, CHINAHONGQIAO increased by 3.9%, and CNOOC rose by 3.7%, while YUM CHINA fell by 4.6%.
Short Selling Trends: High short selling ratios were observed in several stocks, with YUM CHINA at 47.6% and MEITUAN at 25.8%, indicating significant market speculation.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
HSI Ends at 27,266, Gaining 83 Points; HSTI Finishes at 5,499, Up 48 Points; XIAOMI Surges Over 4%; TECHTRONIC IND, CHINA RES MIXC, ZTO EXPRESS-W, WH GROUP, CLP HOLDINGS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 83 points (0.3%) to close at 27,266, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, with market turnover reaching $217.22 billion.
Active Heavyweights: Notable movements included Xiaomi (+4.3%), Ping An (-1.3%), Tencent (-0.5%), and Alibaba (-0.2%), with significant short selling activity across these stocks.
HSI & HSCEI Constituents: Key performers included Pop Mart (-5.5%), Techtronic Industries (+4.9%), and BYD Company (+3.5%), with several stocks hitting new highs despite some declines.
HSMI & HSSI Constituents: Synagistics surged by 38.7%, while KB Laminates and CNBM both rose by over 11%, indicating strong performance in certain sectors despite some stocks experiencing declines.
Citi's Ratings and Target Prices for Chinese Insurers (Table)
Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.
Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".
Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.
Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.
Citi Reports: Upcoming Results Season for Chinese Insurers; China Life Anticipated to Top NBV Growth
Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.
Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.
Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.
Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.
Citi Places CPIC on 90-Day Negative Watch, Anticipates FY25 Performance to Fall Behind Competitors
Citi's Negative Catalyst Watch on CPIC: Citi has initiated a 90-day negative catalyst watch on CPIC (02601.HK), predicting that its FY25 results will underperform compared to peers, with a projected 28% growth in new life insurance business.
Comparative Performance Expectations: The anticipated combined operating ratio for CPIC in FY25 is 98.0%, which is less favorable than major competitors like PICC GROUP and PING AN, whose ratios are forecasted at 97.3% and 97.1%, respectively.
Earnings Growth Projections: CPIC's projected 16% year-over-year earnings increase for FY25 is significantly lower than the expected growth rates of its competitors, such as CHINA TAIPING at 220% and CHINA LIFE at 47%.
Citi's Rating and Target Price: Despite the negative outlook, Citi has rated CPIC as a Buy and set a target price of HKD 44.9.
<Midday Update> HSI Ends Midday at 26,705, Gaining 138 Points; HSTI Reaches 5,367, Up 7 Points; ZIJIN MINING Surges Over 4%; HK & CHINA GAS, CK ASSET, WH GROUP, TIANGONG INT'L, and CONCH VENTURE Achieve New Record Highs
Market Performance: The Hang Seng Index (HSI) rose by 138 points (0.5%) to 26,705, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw slight gains.
Active Heavyweights: Notable movements included HKEX (+0.9%), PING AN (+0.4%), and TENCENT (+0.2%), while XIAOMI, BABA, and MEITUAN experienced minor declines.
Significant Movers: ZIJIN MINING surged by 4.7%, CHINAHONGQIAO increased by 3.9%, and CNOOC rose by 3.7%, while YUM CHINA fell by 4.6%.
Short Selling Trends: High short selling ratios were observed in several stocks, with YUM CHINA at 47.6% and MEITUAN at 25.8%, indicating significant market speculation.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
HSI Ends at 27,266, Gaining 83 Points; HSTI Finishes at 5,499, Up 48 Points; XIAOMI Surges Over 4%; TECHTRONIC IND, CHINA RES MIXC, ZTO EXPRESS-W, WH GROUP, CLP HOLDINGS Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 83 points (0.3%) to close at 27,266, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also saw gains, with market turnover reaching $217.22 billion.
Active Heavyweights: Notable movements included Xiaomi (+4.3%), Ping An (-1.3%), Tencent (-0.5%), and Alibaba (-0.2%), with significant short selling activity across these stocks.
HSI & HSCEI Constituents: Key performers included Pop Mart (-5.5%), Techtronic Industries (+4.9%), and BYD Company (+3.5%), with several stocks hitting new highs despite some declines.
HSMI & HSSI Constituents: Synagistics surged by 38.7%, while KB Laminates and CNBM both rose by over 11%, indicating strong performance in certain sectors despite some stocks experiencing declines.
